Login to Your Account



Financings Roundup

PRISM Banks $15M to Fund Cancer Drug R&D for Fibrosis

By Dave Silver
Staff Writer

Thursday, June 13, 2013
TAIPEI, Taiwan – Diminutive drug discovery firm PRISM Pharma Co. Ltd., of Yokohama, Japan, has closed a Series C round of funding of approximately ¥1.4 billion (US$15 million) with the funds earmarked for upcoming clinical trials for the company's investigative oncology drug PRI-724 in non-oncology related conditions, initially fibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription